Investing.com -- Baird upgraded DexCom Inc (NASDAQ:DXCM). to "Outperform" from "Neutral," citing progress in U.S. sales and upcoming catalysts. The price target was raised to $104 from $98.
DexCom's improved salesforce productivity and the potential for U.S. growth to return to low-to-mid teens by mid-2025 were key drivers. Recent advancements include earlier-than-expected progress on the G7 15-day sensor and potential FDA approval for hospital-based use.
The firm highlighted growing confidence in DexCom’s multi-year pipeline, including the G8 sensor, expected to bring advanced features like ketone monitoring by 2027. Expanding reimbursement for Type 2 diabetes patients is another tailwind.
Baird acknowledged competitive risks from Abbott's Libre 3 and potential Medicare repricing but expects DexCom to deliver revenue growth of 10-15% and EPS growth of 20% over the next 2-3 years.
With these factors, the stock’s valuation could rise to mid-20s multiples, Baird added.
Related Articles
Baird raises DexCom stock to outperform, target to $104
Luxury firms, chipmakers lift Europe's STOXX 600 to five-week high
Cuba releases jailed dissident, rights activist Jose Daniel Ferrer
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。